Home > Insider Trading > Filing (0001213900-22-075598)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
316253	Enzo Biochem Inc	ENZ	Services-Medical Laboratories (8071)	132866202

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1893172	Hamid Erfanian	C/O Enzo Biochem, Inc 81 Executive Blvd., Suite 3 Farmingdale NY 11735	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	Acquisiton	2022-11-23	100,000	$1.97	374,600	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (to acquire Common Stock)	Acquisiton	2022-11-23	300,000	$0.00	300,000	$1.97

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
300,000	2023-11-23	2027-11-23	No	4	A	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (to acquire Common Stock)	$3.39	2022-11-08	2026-11-08	700,000	700,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2026-11-08	700,000	700,000	Direct

Footnotes

The Reporting Person was granted Restricted Stock Units that will vest in three equal installments, beginning on November 23, 2023.
The Reporting Person was granted 300,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 23, 2023.
The Reporting Person was granted 700,000 stock options. The stock options have a five-year term and will vest, subject to the individual's continued employment with Enzo Biochem, Inc., in three equal annual installments, beginning on November 8, 2022.